BioNTech SE (22UA)
XHAN
Closed
Aug 21, 2026
Day's Range
93.9052 wk Range
68.65Overview - 22UA - BioNTech SE
Key Statistics
Valuation
Enterprise Value
-7.40B
P/E (Trailing)
‪-21.20‬
Price / Book
‪1.42‬
EV / EBITDA
‪28.90‬
Profitability
Gross Margin
‪8.14%‬
Profit Margin
‪77.63%‬
Operating Margin
‪-36.11%‬
Return on Assets
‪-5.16%‬
Return on Equity
‪-5.90%‬
Ownership
Shares Outstanding
251.20M
Price stats
50-Day Avg
‪83.02‬
200-Day Avg
‪83.02‬
Peers - 22UA - BioNTech SE
Peer Comparison
Compared with companies in Biotechnology listed on XHAN.
- 22UAXHANBioNTech SE-21.70%52-week change—P/E (Trailing)—Profit Margin
- 0QFXHANModerna, Inc.+82.89%52-week change-17.84P/E (Trailing)‪54.83%‬Profit Margin
- 1AEAXHANargenx SE American Depositary Receipt+34.08%52-week change42.46P/E (Trailing)‪89.14%‬Profit Margin
- ANLXHANAnalog Devices, Inc.+32.46%52-week change69.63P/E (Trailing)‪61.46%‬Profit Margin
- BM8XHANBiomarin Pharmaceutical Inc.+14.63%52-week change31.80P/E (Trailing)‪77.72%‬Profit Margin
- BBZAXHANBB Biotech AG+0.00%52-week change5.58P/E (Trailing)—Profit Margin
- ANTHXHANBrw Stable Return Fund-2.88%52-week change—P/E (Trailing)—Profit Margin
Profile Summary - 22UA - BioNTech SE
About
BioNTech SE is a biotechnology company focused on the development of immunotherapies and mRNA-based medicines for cancer and infectious diseases. The company’s current portfolio includes oncology programs such as personalized and off-the-shelf cancer immunotherapies, cell therapies, and targeted biologic approaches…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
